KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Long-Term Debt Repayments (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Long-Term Debt Repayments for 7 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 99.22% year-over-year, with the annual reading at $5.0 million for FY2025, 99.22% down from the prior year.
  • Long-Term Debt Repayments hit $1.2 million in Q4 2025 for GoodRx Holdings, roughly flat from $1.2 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $633.8 million in Q3 2024 to a low of -$1000.0 in Q4 2023.
  • Historically, Long-Term Debt Repayments has averaged $34.9 million across 5 years, with a median of $1.8 million in 2021.
  • Biggest five-year swings in Long-Term Debt Repayments: tumbled 100.06% in 2023 and later surged 35970.86% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $1.8 million in 2021, then changed by 0.0% to $1.8 million in 2022, then crashed by 100.06% to -$1000.0 in 2023, then skyrocketed by 63376600.0% to $633.8 million in 2024, then tumbled by 99.8% to $1.2 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for GDRX at $1.2 million in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.